DNA damage and repair in normal and neoplastic cells treated with adriamycin

Area of Science:

• Molecular Biology
• Cell Biology
• Pharmacology

Background:

• Adriamycin (ADR) is a widely used antineoplastic drug.
• Understanding its effects on DNA is crucial for cancer treatment.
• Human fibroblasts (CLV98) and melanoma cells (ME18) are relevant models for studying drug toxicity.

Purpose of the Study:

• To investigate DNA repair synthesis in response to Adriamycin.
• To assess cell cytotoxicity of Adriamycin in different human cell lines.
• To analyze DNA single-strand breaks and their repair after Adriamycin exposure.

Main Methods:

• Exposure of CLV98 and ME18 cells to varying concentrations of Adriamycin.
• Measurement of DNA repair synthesis.
• Evaluation of cell cytotoxicity.
• Monitoring of DNA single-strand breaks and their repair dynamics.

Main Results:

• No DNA repair synthesis was observed in either cell type at Adriamycin concentrations up to 10(-5) M.
• ME18 cells exhibited less sensitivity to Adriamycin than CLV98 cells.
• At 1 microgram/ml Adriamycin, DNA single-strand breaks were incompletely repaired in ME18 and unrepaired in CLV98 cells within 24 hours.
• Complete repair of single-strand breaks occurred in both cell types within 48 hours.
• No repair of single-strand breaks was observed at 5 micrograms/ml Adriamycin concentration.

Conclusions:

• Adriamycin does not stimulate DNA repair synthesis in normal human fibroblasts or melanoma cells.
• The repair capacity for Adriamycin-induced DNA damage is limited and concentration-dependent.
• Melanoma cells show greater resistance to Adriamycin's cytotoxic effects compared to fibroblasts.